IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
← catalyst calendarNCT06112314 · readout in 423 d
Sponsored by Immunocore Ltd (industry) · IMCR — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
680estimated
Sites
211
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-05 | actual | When the study began enrolling |
| Primary completion | 2027-10-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-16 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Melanoma
Interventions
- Drug: Brenetafusp — also filed as IMC-F106C
- Drug: Nivolumab — also filed as OPDIVO
- Drug: Nivolumab + Relatlimab — also filed as OPDUALAG
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS)
measured Up to ~45 months
Permalink · IMCR's whole pipeline · Catalyst calendar · Every registered study · What changed